Received Nov 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
how long can I expect the redness, swelling and muscle soreness to last at the injection site; how long can I expect the redness, swelling and muscle soreness to last at the injection site; how long can I expect the redness, swelling and muscle soreness to last at the injection site; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site swelling in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site swelling (Verbatim: how long can I expect the redness, swelling and muscle soreness to last at the injection site), injection site erythema (Verbatim: how long can I expect the redness, swelling and muscle soreness to last at the injection site) and injection site muscle pain (Verbatim: how long can I expect the redness, swelling and muscle soreness to last at the injection site). The outcome of the injection site swelling, injection site erythema and injection site muscle pain were not resolved. It was unknown if the reporter considered the injection site swelling, injection site erythema and injection site muscle pain to be related to Shingrix. It was unknown if the company considered the injection site swelling, injection site erythema and injection site muscle pain to be related to Shingrix. Additional Information: GSK Receipt Date: 30-OCT-2025 This case was reported by a patient via interactive digital media. The batch number was not provided, and we are unable to contact the reporter.